transmembrane protein 242Genealiases: BM033 · C6orf35
Q-omics provides the consensus-scored TMEM242 profile across patient tissues and cancer cell-line models. TMEM242 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TMEM242 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, TMEM242 RNA expression shows 19,361 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KICH, and ACC as cancer lineages where TMEM242 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM242 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM242 survival associations across molecular data types. TMEM242 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM242 RNA expression–survival associations across cancer types. High TMEM242 expression shows unfavorable associations in HNSC, BLCA, BRCA, OV and ACC, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TMEM242 RNA expression.
This table summarizes TMEM242 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM242. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM242 shows lower tumor expression in KICH, THCA, BRCA and COAD and higher tumor expression in HNSC and CHOL. The KICH box plot shows higher TMEM242 RNA expression in normal versus tumor tissue (log2 FC = −0.894, t-test p < 0.001).
This table shows molecular features associated with TMEM242 in patient tissues and cancer cell lines. In patient samples, TMEM242 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM242 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
